Figure S2 Relationship between risk score and efficacy of immunotherapy. (A-D) Kaplan-Meier curves show overall survival in the high-risk (red) and low-risk (blue) subgroups before the immune checkpoint treatment in the GSE91061 (A), PRJEB23709 (B), phs000452.v3 (C), IMvigor210 (D) cohorts. (E-G) Kaplan-Meier curves show progression-free survival in the high-risk (red) and low-risk (blue) subgroups before the immune checkpoint treatment in the GSE135222 (E), PRJEB23709 (F), phs000452.v3 (G) cohorts. p < 0.05 in the two-sided log-rank test was considered statistically significant.